ClinicalTrials.gg
CompletedNCT00410202DEFINEUpdated Nov 21, 2013Results posted

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

A Phase 3 interventional study of Entecavir and Tenofovir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 67 sites in 18 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-11-21.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
629
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
3rd of 61
629 · median 109
Started
2008
with 7 others
Phase 3
13 of 64
none open now
Registered
8th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 3rd largest by enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2008, is one of 13 in phase 3, and was the 8th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of lamivudine (LVD) resistance
  • Subjects must have a history of previous LVD treatment at screening, and must have evidence of at least 1 LVD resistance substitution (valine, isoleucine, or serine) at reverse transcriptase codon 204 (M204V/I/S)
  • Nucleoside- and nucleotide-naive, except for LVD, and had chronic (HBV) infection
  • Compensated liver function and must have met ALL of the following criteria:International normalization ratio () ≤ 1.5; Serum albumin ≥ 3 g/dL (≥ 30 g/L); Serum total ≤ 2.5 mg/dL (≤ 42.75 μmol/L)
  • HBV DNA > 1.72 x 10*4* IU/mL (approximately 10*5* copies/mL)
  • Documentation of hepatitis B e antigen (HBeAg) positive and hepatitis B e antibody (HBeAb) negative status at screening
  • (ALT) ≤ 10 * (ULN) at screening
  • Women of (WOCBP) must be using an adequate method of to avoid pregnancy throughout the study (and for up to 6 weeks after the last dose of product) in such a manner that the risk of pregnancy is minimized
  • WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not . Post menopausal is defined as:
  • Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential
  • WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 72 hours prior to the start of investigational product

Exclusion criteria

Exclusion Criteria:

  • Evidence of decompensated cirrhosis
  • Coinfection with , virus , or hepatitis D virus
  • Women who are pregnant or breastfeeding
  • Sexually active fertile men not using effective if their partners were
  • Laboratory values out of protocol-specified range
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
629 participants (actual)

Study arms

  • Active comparator
    Entecavir

    With the option of adding tenofovir at week 48. (This does not apply to Korea)

    Drug: Entecavir · Drug: Tenofovir

  • Active comparator
    Adefovir + Lamivudine

    Drug: Adefovir · Drug: Lamivudine

  • Active comparator
    Entecavir + Adefovir

    Drug: Entecavir · Drug: Adefovir

Interventions

  • Tablets, Oral, 1mg, once daily, 100 weeks

    Also known as: Baraclude, BMS-200475

  • Tablets, Oral, 300 mg, once daily

    Also known as: Viread

  • Tablets, Oral, 10mg, once daily, 100 weeks

    Also known as: Hepsera

  • Tablets, Oral, 100mg, once daily, 100 weeks

    Also known as: Epivir

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48

    HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay. HBV DNA less than (\<)50 International units per milliliter (IU/mL) = approximately 300 copies/mL. Percentage of participants calculated n/N; n= number of participants with HBV DNA \<50 IU/mL; N = number of participants analyzed.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96

    HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. HBV DNA \< 50 IU/mL = approximately 300 copies/mL. Percentage n/N: n= number of participants with HBV DNA \<50 IU/mL; N = number of participants analyzed.

    Time frame: Week 96

  2. Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48

    HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.

    Time frame: Week 48

  3. Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96

    HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.

    Time frame: Week 96

  4. Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48

    HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.

    Time frame: Week 48

  5. Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96

    HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest amount or concentration of analyte in a sample, which can be reliably detected, but not necessarily quantified.

    Time frame: Week 96

  6. Percentage of Participants With HBV DNA by PCR Category at Week 48

    HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay.

    Time frame: Week 48

  7. Percentage of Participants With HBV DNA by PCR Category at Week 96

    HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay.

    Time frame: Week 96

  8. Change in Mean log10 From Baseline in HBV DNA at Week 48

    HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load, negative values means reduction.

    Time frame: Baseline, Week 48

  9. Change in Mean log10 From Baseline in HBV DNA at Week 96

    HBV DNA was analyzed by PCR, using the Roche COBAS® TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load.

    Time frame: Baseline, Week 96

  10. Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48

    ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 or 48 U/L.

    Time frame: Week 48

  11. Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96

    ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.

    Time frame: Baseline, Week 96

  12. Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)

    HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week

    Time frame: Week 48

  13. Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)

    HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week

    Time frame: Week 96

  14. Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)

    HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).

    Time frame: Week 48

  15. Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)

    HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).

    Time frame: Week 96

  16. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

    HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.

    Time frame: Week 48

  17. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96

    HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.

    Time frame: Week 96

  18. Percentage of Participants With HBsAg Seroconversion at Week 48

    HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.

    Time frame: Week 48

  19. Percentage of Participants With HBsAg Seroconversion at Week 96

    HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.

    Time frame: Week 96

  20. Cumulative Probability of Emergent Genotypic Resistance at Year 1

    yr=year. Cumulative probability (CP): Ptotal=1-(1-Pyr1)\*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).

    Time frame: Year 1

  21. Cumulative Probability of Emergent Genotypic Resistance at Year 2

    Cumulative probability (CP): Ptotal=1-(1-Pyr1)\*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).

    Time frame: Year 2

  22. Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment

    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Grade 1 = mild, Grade 2= moderate, Grade 3 = severe, Grade 4 = life threatening/disabling, Grade 5 = death.

    Time frame: From start of study therapy through Week 100 + 5 days

  23. Number of Participants With Laboratory Abnormalities: Hematology

    Criteria for hematology abnormalities were: Hemoglobin: \<=11.0 g/dL; White Blood Cells: \<4000/mm\^3; Absolute Neutrophils (includes absolute bands): \<1500/mm\^3; Platelets: \<=99,000/mm\^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.

    Time frame: From start of study through Week 100 + 5 days

  24. Number of Participants With Laboratory Abnormalities: Serum Chemistry

    ULN=upper limit of normal (Normal ranges are Central lab data and vary according to the site). ALT:\>1.25\*ULN, AST:\>1.25\*ULN, ALP:\>1.25\*ULN, Total Bilirubin:\>1.1\*ULN, Serum Lipase:\>1.10\*ULN, Creatinine:\>1.1\*ULN, Blood Urea Nitrogen:1.25\*ULN, Hyperglycemia:\>116 mg/dL, Hypoglycemia:\<64 mg/dL, Hyponatremia:\<132meq/L, Hypokalemia:\<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, \<3 g/dL; Hypernatremia:\>148 meq/L, Hyperkalemia:\>5.6 meq/L, Hypokalemia:\<3.4 meq/L, Hyperchloremia:\>113 meq/L, Hypochloremia:\<93 meq/L; ALT flare: on treatment (OT), \>2\*Baseline and \>10\*ULN; off treatment (OF), 2\*end of dosing value and \>10\*ULN

    Time frame: On treatment : Day 1 through Week 100 + 5 days; Offtreatment = End of OT period through 24 weeks

07

Results

Posted Jul 4, 2012

Participant flow

A total of 629 participants were enrolled at 60 sites.

On-Treatment
Participant flow — On-Treatment
MilestoneEntecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination Therapy
Started138140137
Discontinued prior to week 48 visit422
Discontinued at or after week 48 visit263
Completed636166
Not completed757971
Withdrew: Continuing treatment697166
Withdrew: Adverse event132
Withdrew: Death100
Withdrew: Lost to follow-up101
Withdrew: Lack of efficacy140
Withdrew: Withdrawal by subject211
Withdrew: Other reason001
Off-treatment Follow up
Participant flow — Off-treatment Follow up
MilestoneEntecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination Therapy
Started15814
Completed102
Not completed14812
Withdrew: Continuing off-treatment follow up10811
Withdrew: Follow up not required per protocol301
Withdrew: Lost to follow-up100

Outcome measures

PrimaryPercentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay. HBV DNA less than (\<)50 International units per milliliter (IU/mL) = approximately 300 copies/mL. Percentage of participants calculated n/N; n= number of participants with HBV DNA \<50 IU/mL; N = number of participants analyzed.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 4825.416.419.7
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Hochberg procedure · p = 0.1336 · Difference estimate: 8.9 · 95% CI -2.0 to 19.9
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Hochberg procedure · p = 0.2619 · Difference estimate: 5.7 · 95% CI -4.2 to 15.5
SecondaryPercentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. HBV DNA \< 50 IU/mL = approximately 300 copies/mL. Percentage n/N: n= number of participants with HBV DNA \<50 IU/mL; N = number of participants analyzed.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96
Percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 9643.539.328.5
Statistical analysis
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Hochberg procedure · p = 0.0095 · Difference estimate: 15.0 · 95% CI 3.7 to 26.4
SecondaryPercentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 4825.413.616.8
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Difference estimate: 11.8 · 95% CI 2.5 to 21.1
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: 8.6 · 95% CI -1.1 to 18.2
SecondaryPercentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96
Percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 9638.436.425.5
Statistical analysis
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: 12.9 · 95% CI 1.8 to 23.9
SecondaryPercentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 4820.311.411.7
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Difference estimate: 8.9 · 95% CI 0.3 to 17.4
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: 8.6 · 95% CI -0.1 to 17.3
SecondaryPercentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest amount or concentration of analyte in a sample, which can be reliably detected, but not necessarily quantified.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 9633.327.120.4
Statistical analysis
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: 12.9 · 95% CI 2.4 to 23.4
SecondaryPercentage of Participants With HBV DNA by PCR Category at Week 48

HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA by PCR Category at Week 48
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
< LOQ (29 IU/mL)25.413.616.8
LOQ to < 5002.92.9
50 to < 1728.02.95.8
172 to < 1,72026.17.912.4
1,720 to < 17,20028.322.131.4
17,200 to < 172,0008.025.724.8
>= 172,0000.723.64.4
Missing3.61.41.5
SecondaryPercentage of Participants With HBV DNA by PCR Category at Week 96

HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA by PCR Category at Week 96
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
< LOQ (29 IU/mL)38.436.425.5
LOQ to < 505.12.92.9
50 to < 17210.13.65.8
172 to < 1,72015.26.418.2
1,720 to < 17,20020.310.024.8
17,200 to < 172,0005.815.713.9
>= 172,000016.42.9
Missing5.18.65.8
SecondaryChange in Mean log10 From Baseline in HBV DNA at Week 48

HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load, negative values means reduction.

Time frame:
Baseline, Week 48
Reported as:
Mean · log10 (IU/mL
Change in Mean log10 From Baseline in HBV DNA at Week 48
log10 (IU/mLETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
HBV DNA at Week 482.79 ± 0.0934.01 ± 0.1283.36 ± 0.111
Change from baseline-4.65 ± 0.077-3.35 ± 0.117-4.11 ± 0.108
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Regression, Linear · Difference estimate: -1.26 · 95% CI -1.534 to -0.994
  • ETV Monotherapy vs ADV+LVD Combination Therapy · Regression, Linear · Difference estimate: -0.55 · 95% CI -0.824 to -0.281
SecondaryChange in Mean log10 From Baseline in HBV DNA at Week 96

HBV DNA was analyzed by PCR, using the Roche COBAS® TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load.

Time frame:
Baseline, Week 96
Reported as:
Mean · participants
Change in Mean log10 From Baseline in HBV DNA at Week 96
participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Change in Mean log10 From Baseline in HBV DNA at Week 96-5.06 ± 0.090-4.17 ± 0.163-4.49 ± 0.116
SecondaryPercentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48

ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 or 48 U/L.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 4875.678.076.8
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Difference estimate: -2.4 · 95% CI -15.5 to 10.7
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: -1.2 · 95% CI -15.0 to 12.6
SecondaryPercentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96

ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.

Time frame:
Baseline, Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 9676.974.479.7
Statistical analysis
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: -2.8 · 95% CI -16.2 to 10.6
SecondaryPercentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)

HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)7.26.55.9
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Difference estimate: 0.8 · 95% CI -5.2 to 6.7
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: 1.3 · 95% CI -4.6 to 7.2
SecondaryPercentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)

HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)12.310.713.9
Statistical analysis
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: -1.5 · 95% CI -9.5 to 6.4
SecondaryPercentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)

HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)5.12.93.7
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Difference estimate: 2.2 · 95% CI -2.4 to 6.8
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: 1.4 · 95% CI -3.5 to 6.2
SecondaryPercentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)

HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)7.23.65.1
Statistical analysis
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: 2.1 · 95% CI -3.6 to 7.8
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 480.700.7
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Difference estimate: 0.7 · 95% CI -0.7 to 2.1
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: -0.0 · 95% CI -2.0 to 2.0
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96000
SecondaryPercentage of Participants With HBsAg Seroconversion at Week 48

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at Week 48
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With HBsAg Seroconversion at Week 480.700
Statistical analysis
  • ETV+ADV Combination Therapy vs ETV Monotherapy · Difference estimate: 0.7 · 95% CI -0.7 to 2.1
  • ETV+ADV Combination Therapy vs ADV+LVD Combination Therapy · Difference estimate: 0.7 · 95% CI -0.7 to 2.1
SecondaryPercentage of Participants With HBsAg Seroconversion at Week 96

HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at Week 96
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Percentage of Participants With HBsAg Seroconversion at Week 96000
SecondaryCumulative Probability of Emergent Genotypic Resistance at Year 1

yr=year. Cumulative probability (CP): Ptotal=1-(1-Pyr1)\*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).

Time frame:
Year 1
Reported as:
Number · percentage of participants
Cumulative Probability of Emergent Genotypic Resistance at Year 1
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
ETVr : n=134, 134, 134030.7
ADVr /TDFr : n=137, 137, 1350.70.71.5
ETVr or TDFr/ADVr : n=133, 132, 1320.83.82.3
ETVr and TDFr/ADVr : n=138, 139, 137000
ETVr with VBT: n=134, 134, 13400.70
ADVr /TDFr with VBT: n=137, 137, 135000
ETVr or ADVr/TDFr with VBT: n=133, 132, 13200.80
ETVr and ADVr/TDFr with VBT: n=138, 139, 137000
SecondaryCumulative Probability of Emergent Genotypic Resistance at Year 2

Cumulative probability (CP): Ptotal=1-(1-Pyr1)\*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).

Time frame:
Year 2
Reported as:
Number · percentage of participants
Cumulative Probability of Emergent Genotypic Resistance at Year 2
percentage of participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
ETVr : n=130, 128, 1310.89.81.5
ADVr/TDFr : n=132, 134, 1310.71.52.2
ETVr or ADVr/TDFr : n=128, 125, 1271.510.73.8
ETVr and ADVr/TDFr : n=134, 137, 13500.70
ETVr with VBT: n=130, 128, 13106.20
ADVr/TDFr with VBT: n=132, 134, 13100.70
ETVr or ADVr/TDFr with VBT: n=128, 125, 12706.30
ETVr and ADVr/TDFr with VBT: n=134, 137, 13500.70
SecondaryParticipants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Grade 1 = mild, Grade 2= moderate, Grade 3 = severe, Grade 4 = life threatening/disabling, Grade 5 = death.

Time frame:
From start of study therapy through Week 100 + 5 days
Reported as:
Number · participants
Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment
participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Deaths001
SAEs111712
Discontinuations due to AEs122
AEs10110992
Grade 2-4 Related AEs2121
Grade 3-4 Related AEs579
SecondaryNumber of Participants With Laboratory Abnormalities: Hematology

Criteria for hematology abnormalities were: Hemoglobin: \<=11.0 g/dL; White Blood Cells: \<4000/mm\^3; Absolute Neutrophils (includes absolute bands): \<1500/mm\^3; Platelets: \<=99,000/mm\^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.

Time frame:
From start of study through Week 100 + 5 days
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities: Hematology
participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Hemoglobin8911
White Blood Cells534838
Neutrophils141715
Platelets131412
International Normalized Ratio879
SecondaryNumber of Participants With Laboratory Abnormalities: Serum Chemistry

ULN=upper limit of normal (Normal ranges are Central lab data and vary according to the site). ALT:\>1.25\*ULN, AST:\>1.25\*ULN, ALP:\>1.25\*ULN, Total Bilirubin:\>1.1\*ULN, Serum Lipase:\>1.10\*ULN, Creatinine:\>1.1\*ULN, Blood Urea Nitrogen:1.25\*ULN, Hyperglycemia:\>116 mg/dL, Hypoglycemia:\<64 mg/dL, Hyponatremia:\<132meq/L, Hypokalemia:\<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, \<3 g/dL; Hypernatremia:\>148 meq/L, Hyperkalemia:\>5.6 meq/L, Hypokalemia:\<3.4 meq/L, Hyperchloremia:\>113 meq/L, Hypochloremia:\<93 meq/L; ALT flare: on treatment (OT), \>2\*Baseline and \>10\*ULN; off treatment (OF), 2\*end of dosing value and \>10\*ULN

Time frame:
On treatment : Day 1 through Week 100 + 5 days; Offtreatment = End of OT period through 24 weeks
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities: Serum Chemistry
participantsETV+ADV Combination TherapyETV MonotherapyADV+LVD Combination Therapy
Alanine aminotransferase (ALT)768374
Aspartate aminotransferase (AST)606253
Alkaline Phosphatase (ALP)846
Albumin111
Serum Lipase243324
Creatinine224
Blood Urea Nitrogen012
Hyperglycemia394637
Hypoglycemia959
Hypernatremia101010
Hyponatremia000
Hyperkalemia345
Hypokalemia422
Hyperchloremia111
Hypochloremia100
ALT flare - Ontreatment322
ALT flare - Offtreatment000

Adverse events

Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADV + LVD Combination Therapy—13/137 (9.5%)62/137 (45.3%)
ETV Monotherapy—21/140 (15%)75/140 (53.6%)
ETV + ADV Combination Therapy—14/138 (10.1%)63/138 (45.7%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventADV + LVD Combination TherapyETV MonotherapyETV + ADV Combination Therapy
Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1375/1404/138
HaemorrhoidsGastrointestinal disorders0/1373/1401/138
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1370/1402/138
AppendicitisInfections and infestations0/1372/1401/138
Oesophageal varices haemorrhageGastrointestinal disorders1/1371/1400/138
Intracranial hypotensionNervous system disorders1/1370/1400/138
MelaenaGastrointestinal disorders1/1370/1400/138
DizzinessNervous system disorders1/1370/1400/138
SpondylolisthesisMusculoskeletal and connective tissue disorders1/1370/1400/138
Wrist fractureInjury, poisoning and procedural complications1/1371/1401/138
Most frequent other events
Showing 10 of 13
Most frequent other events
EventADV + LVD Combination TherapyETV MonotherapyETV + ADV Combination Therapy
Upper respiratory tract infectionInfections and infestations19/13728/14023/138
NasopharyngitisInfections and infestations8/13717/14017/138
HeadacheNervous system disorders13/1375/1408/138
DyspepsiaGastrointestinal disorders8/1376/14010/138
Abdominal pain upperGastrointestinal disorders6/13710/1405/138
Hepatic steatosisHepatobiliary disorders9/1378/1404/138
FatigueGeneral disorders8/1374/1404/138
Abdominal discomfortGastrointestinal disorders7/1373/1408/138
Alanine aminotransferase increasedInvestigations5/1378/1408/138
NauseaGastrointestinal disorders4/1378/1406/138

Baseline characteristics

Age Continuous
Age Continuous(years)Entecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination TherapyTotal
Median46.0 (18 to 69)43.5 (19 to 71)43.0 (16 to 74)45.0 (16 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Entecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination TherapyTotal
Female475240139
Male918897276
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Entecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination TherapyTotal
Asian132131126389
White691126
Region of Enrollment
Region of Enrollment(participants)Entecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination TherapyTotal
Australia0112
Canada1001
Hong Kong57517
India43512
Indonesia0101
Italy1001
Korea, Republic of108105102315
Malaysia3025
Philippines0112
Poland59923
Russian Federation0022
Singapore1102
Taiwan89926
Thailand1315
Turkey1001
Hepatitis B surface antigen (HBsAg) status at baseline
Hepatitis B surface antigen (HBsAg) status at baseline(participants)Entecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination TherapyTotal
Positive138140137415
Negative0000
Hepatitis B e antigen (HBeAg) status at baseline
Hepatitis B e antigen (HBeAg) status at baseline(participants)Entecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination TherapyTotal
Positive138139135412
Negative0123
Hepatitis B e antibody (HBeAb) at baseline
Hepatitis B e antibody (HBeAb) at baseline(participants)Entecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination TherapyTotal
Positive0123
Negative138139135412
Alanine Aminotransferase (ALT)
Alanine Aminotransferase (ALT)(U/L)Entecavir + Adefovir (ETV+ADV) Combination TherapyEntecavir (ETV) MonotherapyAdefovir + Lamivudine (ADV+LVD) Combination TherapyTotal
Median49 (10 to 480)50 (12 to 367)45 (14 to 1300)47 (10 to 1300)

5 further baseline measures are reported on the registry.

08

Study locations

67 sites
  • University Of Connecticut Health Center
    Farmington, Connecticut 06030, United States
  • Local Institution
    Concord, New South Wales 2139, Australia
  • Local Institution
    Randwick, New South Wales 2031, Australia
  • Local Institution
    Porto Alegre Rs, Rio Grande Do Sul 90035, Brazil
  • Local Institution
    Calgary, Alberta T2N 4N1, Canada
  • Local Institution
    Athens, 11527, Greece
  • Local Institution
    Shatin, New Territories, Hong Kong
  • Local Institution
    Hong Kong, Hong Kong
  • Local Institution
    Tai Po, Hong Kong
  • Local Institution
    Lucknow, Uttar Pradesh 226014, India
  • Local Institution
    Ahmedabad, 380006, India
  • Local Institution
    Chandigarh, 160012, India
  • Local Institution
    Indore, 452014, India
  • Local Institution
    Ludhiana, 141001, India
  • Local Institution
    New Delhi, 110002, India
  • Local Institution
    Vellore, 632004, India
  • Local Institution
    Jakarta, 10350, Indonesia
  • Local Institution
    Antella, Firenze, 50012, Italy
  • Local Institution
    Seoul, Dongdaemun-Gu 130-702, Korea, Republic of
  • Local Institution
    Ulsan, Donggu 682-714, Korea, Republic of
  • Local Institution
    Ansan-Si, Gyeonggi-Do 425-707, Korea, Republic of
  • Local Institution
    Anyang-Si, Gyeonggi-Do 431-070, Korea, Republic of
  • Local Institution
    Bucheon-Si, Gyeonggi-Do 420767, Korea, Republic of
  • Local Institution
    Seongnam-Si, Gyeonggi-Do 463 712, Korea, Republic of
  • Local Institution
    Suwon-Si, Gyeonggi-Do 442-723, Korea, Republic of
  • Local Institution
    Koyang, Ilsanseo Gu 411-706, Korea, Republic of
  • Local Institution
    Incheon, Jung-Gu 400-711, Korea, Republic of
  • Local Institution
    Seoul, Nowon-Gu 139-872, Korea, Republic of
  • Local Institution
    Chuncheon-Si, 200-704, Korea, Republic of
  • Local Institution
    Daegu, 700-721, Korea, Republic of
  • Local Institution
    Gangneung, 210-711, Korea, Republic of
  • Local Institution
    Incheon, 405-760, Korea, Republic of
  • Local Institution
    Pusan, 602-739, Korea, Republic of
  • Local Institution
    Seoul, 110-744, Korea, Republic of
  • Local Institution
    Seoul, 120-752, Korea, Republic of
  • Local Institution
    Seoul, 135-710, Korea, Republic of
  • Local Institution
    Seoul, 135-720, Korea, Republic of
  • Local Institution
    Seoul, 136-705, Korea, Republic of
  • Local Institution
    Seoul, 137-040, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
  • Local Institution
    Seoul, 143-729, Korea, Republic of
  • Local Institution
    Seoul, 152-703, Korea, Republic of
  • Local Institution
    Seoul, 156-755, Korea, Republic of
  • Local Institution
    Suwon, 443-721, Korea, Republic of
  • Local Institution
    Yangsan-Si, 626770, Korea, Republic of
  • Local Institution
    Kota Kinabalu, Sabah 88586, Malaysia
  • Local Institution
    Kuala Lumpur, 50603, Malaysia
  • Local Institution
    Cebu City, 6000, Philippines
  • Local Institution
    Manila, 1502, Philippines
  • Local Institution
    Chorzow, 41-500, Poland
  • Local Institution
    Kielce, 25-317, Poland
  • Local Institution
    Lodzi, 91-347, Poland
  • Local Institution
    Lublin, 20-081, Poland
  • Local Institution
    Warszawa, 01-201, Poland
  • Local Institution
    Moscow, 105275, Russian Federation
  • Local Institution
    Moscow, 115446, Russian Federation
  • Local Institution
    St. Petersburg, 190103, Russian Federation
  • Local Institution
    St. Petersburg, 191167, Russian Federation
  • Local Institution
    Singapore, 119074, Singapore
  • Local Institution
    Kaohsiung, 80756, Taiwan
  • Local Institution
    Tainan R.O.C., 70403, Taiwan
  • Local Institution
    Taipei, 100, Taiwan
  • Local Institution
    Taoyuan, 333, Taiwan
  • Local Institution
    Bangkok, 10700, Thailand
  • Local Institution
    Chiang Mai, 50200, Thailand
  • Local Institution
    Bornova Izmir, 35100, Turkey
  • Local Institution
    Trabzon, 610808, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jan 2011 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2006
First posted
Dec 12, 2006
Start
Mar 2008
Primary completionActual
Jan 2011
CompletionActual
Jul 2012
Results first posted
Jul 4, 2012
Last update
Nov 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00410202
Responsible party
Sponsor
First posted
Dec 12, 2006
Start date
Mar 2008
Primary completion
Jan 2011
Completion
Jul 2012
Results posted
Jul 4, 2012
Last update
Nov 21, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Entecavir · Tenofovir · Adefovir · Lamivudine

Start the discussion